Pfizer Inc. (PFE) Financials
PeriodQ2 FY2026
Published
Pfizer reported $15.03 billion in total revenues for Q2 FY2026, the quarter ended June 28, 2026, up 2.6% from a year earlier. The company posted a net loss of $248 million, or $0.04 per diluted share, against net income of $2.91 billion in the same quarter a year earlier; the swing came from charges rather than from the underlying business, chiefly intangible asset impairments tied to a failed late-stage lung cancer study and to the withdrawal of Oxbryta in the United States, plus charges for certain legal matters, only partly offset by a gain on the sale of Pfizer's ViiV investment. Eliquis remained the largest single product at $2.42 billion, up 21.1%, while research and development spending rose to $2.81 billion, up 13.2%, on oncology and obesity candidates.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $15,034,000,000 | up 2.6% |
| Net income | -$248,000,000 | swung from $2.91 billion |
| Diluted EPS | -$0.04 | swung from $0.51 |
| R&D expenses | $2,809,000,000 | up 13.2% |
| Eliquis revenue | $2,425,000,000 | up 21.1% |
Company details
| Name | Pfizer Inc |
|---|---|
| Ticker | PFE |
| CIK | 0000078003 |
| Exchange | NYSE |
| State | New York |
| Incorporation | Delaware |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
| Latest period covered | Q2 FY2026, ended 2026-06-28, 10-Q, accession 0000078003-26-000095 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 10-Q around 2026-11-03 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Pfizer Q2 FY2026
How much revenue did Pfizer report in Q2 FY2026?
Pfizer reported $15.03 billion in total revenues for Q2 FY2026, the quarter ended June 28, 2026. That is up 2.6% from $14.65 billion in the same quarter a year earlier.
Did Pfizer make a profit in Q2 FY2026?
No. Pfizer posted a net loss attributable to common shareholders of $248 million in Q2 FY2026, the quarter ended June 28, 2026, against net income of $2.91 billion in the same quarter a year earlier. Loss per diluted share was $0.04, against earnings of $0.51 a share in the year-ago quarter.
Why did Pfizer report a loss in Q2 FY2026?
Pfizer's loss in Q2 FY2026 came from charges rather than from a decline in the business: total revenues were $15.03 billion, up 2.6% from a year earlier, but the quarter carried large intangible asset impairments, most of them against in-process research after a Phase 3 study of sigvotatug vedotin in previously treated advanced non-squamous non-small cell lung cancer missed its primary endpoint, together with a write-down of Oxbryta rights and charges for certain legal matters. A gain on the sale of Pfizer's ViiV investment offset part of that.
How much did Eliquis make for Pfizer in Q2 FY2026?
Eliquis generated $2.42 billion of revenue for Pfizer in Q2 FY2026, the quarter ended June 28, 2026, up 21.1% from $2.00 billion a year earlier. It is Pfizer's largest single product and faces United States generic entry later this decade.
How much does Pfizer spend on research and development?
Pfizer recorded $2.81 billion of research and development expenses in Q2 FY2026, the quarter ended June 28, 2026, up 13.2% from $2.48 billion a year earlier, with the increase driven by spending on certain oncology and obesity candidates.
Where can I get Pfizer Inc. (PFE) financial data in machine-readable form?
Ticker Scout publishes Pfizer Inc.'s financial statements as JSON at https://tickerscout.ai/pfe/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/pfe/narrative.md and https://tickerscout.ai/pfe/events.md. Pfizer Inc.'s SEC CIK is 0000078003. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Pfizer Inc. (PFE) next file with the SEC?
Pfizer Inc. (PFE) is expected to file its next Form 10-Q with the SEC on or around November 3, 2026. That date is a projection rather than a company-announced date: it is derived from Pfizer Inc.'s own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-28, SEC accession 0000078003-26-000095.
Related companies
How this page was built
This page was built from Pfizer Inc.'s own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names five such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.